ArticleBMC biotechnology2026
Au-IDE/LFA biosensor: an integrated sensing platform with lateral flow immunoassay for quantitative detection of hCG hormone using non-faradaic continuous FFT-admittance voltammetry.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of the novel Au-IDE/LFA (gold interdigitated electrode with lateral flow immunoassay) biosensor, an integrated electrochemical sensing platform with lateral flow immunoassay, for quantitative detection of hCG (human Chorionic Gonadotropin) hormone levels is successfully directed here. To fabricate the Au-IDE/LFA setup, a free multi-electrode array of AU-IDE was configured exactly on five zones of LFA on the flow direction, employing non-faradaic measurements through a combination of two electrodes. The impedance behavior of each zone, connected with an Au surface electrode in the Au-IDE/LFA setup was characterized by frequency response analysis (FRA) using non-faradaic electrochemical impedance spectroscopy. Precisely, FRA validated that Au surfaces exhibit similar current homogeneity due to produce the repeatable impedance. The assay optimization using CFFT (Continuous Fast Fourier Transform)-admittance voltammetry, a new method, pinpointed that optimizing the excitation potential by utilizing lower SW frequencies at 88 Hz, amplitude at 10 mV, and DC potential at 10 mV resulted in excellent admittance responses of Au-IDE/LFA biosensor. Both bare and standard LFA were used for signal baseline establishment to ignore the background signal noise induced by the anti-β-hCG-AuNPs (6.01 µA/V), PBS buffer (11.51 µA/V), and urine background (22.11 µA/V). Admittance response showed a high sensitivity about three times more than impedance response with limit of detection by 2.53 mIU/mL in a linear range of 5-500 mIU/mL for hCG with R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.